ODAC Backs Allos' Folotyn Despite Fickle Data, Finds Many Paths Forward

Despite short response duration and a significant number of response adjudications, The Oncologic Drugs Advisory Committee presented numerous paths forward for Allos' peripheral T-cell lymphoma agent Folotyn (pralatrexate)